Comparison of Efficacy of intra-articular shoulder injection between superomedial and anterosuperior approaches in adhesive capsulitis: randomized-controlled trial study

Comparison of Efficacy of intra-articular glenohumeral joint injection between superomedial and anterosuperior approaches in patients with adhesive capsulitis: randomized-controlled trial study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210923005

Enrollment

Registered

2021-09-23

Start date

2021-07-22

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary frozen shoulder primary frozen shoulder

Interventions

entry point at triangular area interval between acromioclavicular joint, coracoid process of the scapula and lesser tubercle of humerus with point 45 degrees caudally,entry point 1 cm posterior to dis

Active Comparator Procedure/Surgery,Active Comparator Procedure/Surgery

anterosuperior approach,superomedial approach

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: patient who was diagnosed to primary frozen shouder

Exclusion criteria

Exclusion criteria: 1. history of massive rotator cuff tear, shoulder instability (unidirectional or multidirectional), and post-traumatic shoulder injury (previous fracture or dislocation around the shoulder fracture of the distal clavicle, scapula, or proximal humerus, acromioclavicular dislocation 2. history of physical theray at affected shoulder or receiced intraarticular steroid injection within 3 mo 3. history of steroid, NSAIDs, Paracetamol, lidocaine or contrast media allergy 4. history of dyspepsia or peptic ulcer 5.history of recurrent frozen shoulder

Design outcomes

Primary

Measure	Time frame
ASES 1 month questionaire	—

Secondary

Measure	Time frame
ASES 1 week questionaire,ASES 3 months questionaire,VAS periinjection interview,VAS immediate postinjection interview,VAS 1 week interview,VAS 1 month interview,VAS 3 months interview,OSS 1 week questionaire,OSS 1 month questionaire,OSS 3 months questionaire,Shoulder forward flexion 1 week, 1 month, 3 months postinjection angle measurement,Shoulder Abduction 1 week, 1 month, 3 months postinjection angle measurement,Shoulder internal rotation 1 week, 1 month, 3 months postinjection angle measurement,Shoulder external rotation 1 week, 1 month, 3 months postinjection angle measurement	—

Measure

Time frame

ASES 1 week questionaire,ASES 3 months questionaire,VAS periinjection interview,VAS immediate postinjection interview,VAS 1 week interview,VAS 1 month interview,VAS 3 months interview,OSS 1 week questionaire,OSS 1 month questionaire,OSS 3 months questionaire,Shoulder forward flexion 1 week, 1 month, 3 months postinjection angle measurement,Shoulder Abduction 1 week, 1 month, 3 months postinjection angle measurement,Shoulder internal rotation 1 week, 1 month, 3 months postinjection angle measurement,Shoulder external rotation 1 week, 1 month, 3 months postinjection angle measurement

—

Countries

Thailand

Contacts

Public ContactChutipong Sookpattee

Thammasat university hospital

chutipongsookpattee@gmail.com0841155879

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026